Anti‐PD‐L1/TGF‐βR fusion protein (SHR‐1701) overcomes disrupted lymphocyte recovery‐induced resistance to PD‐1/PD‐L1 inhibitors in lung cancer

BACKGROUND: Second‐generation programmed cell death‐protein 1/programmed death‐ligand 1 (PD‐1/PD‐L1) inhibitors, such as bintrafusp alfa (M7824), SHR‐1701, and YM101, have been developed to simultaneously block PD‐1/PD‐L1 and transforming growth factor‐beta/transforming growth factor‐beta receptor (...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Bo, Ding, Kaikai, Chen, Pengxiang, Ji, Jianxiong, Luo, Tao, Guo, Xiaofan, Qiu, Wei, Ma, Chunhong, Meng, Xue, Wang, Jian, Yu, Jinming, Liu, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753312/
https://www.ncbi.nlm.nih.gov/pubmed/34981670
http://dx.doi.org/10.1002/cac2.12244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8753312/
https://www.ncbi.nlm.nih.gov/pubmed/34981670
http://dx.doi.org/10.1002/cac2.12244

Ejemplares similares